CoChat

Primary resistance to flucytosine among clinical isolates of Candida spp.

Barchiesi, F., Arzeni, D., Caselli, F., Scalise, G. · 2000 · Journal of Antimicrobial Chemotherapy
Cited by 53

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Sir, Fungal infections caused by common new and emerging yeast and mould pathogens are increasing in frequency, largely as a result of greater numbers of immunocompromised patients.1 Azole drugs are commonly used as treatment for patients with superficial and mild to moderate systemic mycoses, but 5-flucytosine (5FC) is administered, almost always in combination with amphotericin B, to most of those with severe systemic yeast and mould infections.2,3 The present study was undertaken to determine the susceptibilities to 5FC of 179 Candida spp. strains. The isolates studied included 97 strains of Candida albicans, 30 of Candida tropicalis, 22 each of Candida parapsilosis and Candida glabrata and eight of Candida krusei. The strains were non-replicate and none of the patients from whom they were isolated had recently received antifungal therapy. Eighty-one strains (52 C. albicans, 22 C. glabrata and eight C. krusei) were isolated from human immunodeficiency virus (HIV)-infected patients, and the remaining 98 strains were recovered from HIV-negative patients. Susceptibility to 5FC was determined by a microbroth dilution method recommended by the National Committee for Clinical Laboratory Standards (NCCLS).4 5FC was tested at concentrations ranging from 0.125 to 64 mg/L and C. albicans ATCC 76615 and C. krusei ATCC 6258 were used as controls. Each strain was assigned to a susceptibility category according to the following MIC breakpoints recommended by the NCCLS:4 susceptible ≤4 mg/L; intermediate susceptibility 8–16 mg/L; and resistant ≥32 mg/L. The results are summarized in the Table. Overall, 173/ 179 (97%) of the isolates were susceptible to 5FC, but 2/179 (1%) and 4/179 (2%) were intermediately susceptible and resistant, respectively. There was no statistically significant difference between isolates recovered from HIV-positive and HIV-negative patients in terms of susceptibility to 5FC (Mann–Whitney U test; P = 0.16). Although we have evaluated a relatively small number of clinical isolates, we have shown that 5FC possesses excellent in vitro activity against the most common Candida spp. The relationship between resistance to 5FC in C. albicans and serological type has been investigated by Drouhet et al., who reported that the percentage of 5FC-resistant strains isolated from patients in Africa was higher than that recovered from patients in Europe.5 They suggested that the high incidence of resistance (85%) among the former strains was related to the predominance of serotype B isolates, which are recovered more frequently from black people, in contrast to the low incidence of resistance (1%) among serotype A isolates, which are encountered predominantly in white people.5,6 The absence in this study of C. albicans strains resistant to 5FC on primary isolation can be explained by the fact that all of our isolates belonged to serotype A. We identified two species, C. glabrata and C. krusei, whose isolates exhibited reduced susceptibility to 5FC. This observation suggests that the use of 5FC as treatment for patients with fungal infections caused by strains belonging to these species should be avoided unless they are known to be susceptible. To our knowledge this is the first report describing the patterns of susceptibility to 5FC among common clinical yeast isolates based on NCCLS interpretative breakpoints. Table.In vitro susceptibilities of 179 clinical isolates of Candida spp. to 5FC Table.In vitro susceptibilities of 179 clinical isolates of Candida spp. to 5FC

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jac/45.3.408

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

Metadata

Authors
Barchiesi, F., Arzeni, D., Caselli, F., & Scalise, G.
Venue
Journal of Antimicrobial Chemotherapy
Published
2000-03
Volume
45
Issue
3
Pages
408-409
ISSN
  • 0305-7453 (ISSN-L)
  • 1460-2091
OpenAlex
W2150551667
Cited by
53
References
1
FWCI
2.07
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.